This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Osamu Fukuyama, MD
Honolulu, Hawaii

Arch Intern Med. 1991;151(8):1669-1670.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor —

Deedwania¹ presented an excellent review on the use of ACE inhibitors in congestive heart failure, but I do not believe there is enough data to support his conclusion that "... a short-acting ACE inhibitor such as captopril may be preferred for the treatment of selected patients with CHF [congestive heart failure] to minimize these risks."

Although he had mentioned the interim report of the multicenter lisinoprilcaptopril congestive heart failure study group,² his article omitted their final report³ that showed that lisinopril was superior in improving ejection fraction, functional capacity, and quality of life and that it produced fewer serious adverse experiences compared with captopril.

At present, the data are inconclusive regarding the superiority of one ACE inhibitor over other agents, and absolutely agree with Jessup's opinion that "... unfortunately, until more research is accomplished, the choice of an ACE inhibitor for the patient with heart . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?